Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus DRIXORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus DRIXORAL.
ACUVUE THERAVISION WITH KETOTIFEN vs DRIXORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine/Decongestant